Compare Stocks

4 / 10
Try these comparisons:

Stock Comparison

NPCE vs ISRG vs MDT vs BSX

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
NPCE
NeuroPace, Inc.

Medical - Devices

HealthcareNASDAQ • US
Market Cap$648M
5Y Perf.-20.2%
ISRG
Intuitive Surgical, Inc.

Medical - Instruments & Supplies

HealthcareNASDAQ • US
Market Cap$161.07B
5Y Perf.+57.3%
MDT
Medtronic plc

Medical - Devices

HealthcareNYSE • IE
Market Cap$99.94B
5Y Perf.-40.5%
BSX
Boston Scientific Corporation

Medical - Devices

HealthcareNYSE • US
Market Cap$84.08B
5Y Perf.+29.8%

NPCE vs ISRG vs MDT vs BSX — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
NPCE logoNPCE
ISRG logoISRG
MDT logoMDT
BSX logoBSX
IndustryMedical - DevicesMedical - Instruments & SuppliesMedical - DevicesMedical - Devices
Market Cap$648M$161.07B$99.94B$84.08B
Revenue (TTM)$100M$10.58B$35.48B$20.07B
Net Income (TTM)$-32M$2.98B$4.61B$2.89B
Gross Margin77.2%66.3%61.9%69.0%
Operating Margin-16.3%30.5%17.9%19.8%
Forward P/E43.8x14.1x16.7x
Total Debt$71M$303M$28.52B$12.42B
Cash & Equiv.$22M$3.37B$2.22B$2.04B

NPCE vs ISRG vs MDT vs BSXLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

NPCE
ISRG
MDT
BSX
StockApr 21May 26Return
NeuroPace, Inc. (NPCE)10079.8-20.2%
Intuitive Surgical,… (ISRG)100157.3+57.3%
Medtronic plc (MDT)10059.5-40.5%
Boston Scientific C… (BSX)100129.8+29.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: NPCE vs ISRG vs MDT vs BSX

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: MDT leads in 3 of 7 categories, making it the strongest pick for valuation and capital efficiency and dividend income and shareholder returns. NeuroPace, Inc. is the stronger pick specifically for growth and revenue expansion and recent price momentum and sentiment. ISRG and BSX also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
NPCE
NeuroPace, Inc.
The Growth Play

NPCE is the #2 pick in this set and the best alternative if growth exposure is your priority.

  • Rev growth 25.1%, EPS growth 29.0%, 3Y rev CAGR 30.0%
  • 25.1% revenue growth vs MDT's 3.6%
  • +59.2% vs BSX's -46.0%
Best for: growth exposure
ISRG
Intuitive Surgical, Inc.
The Long-Run Compounder

ISRG is the clearest fit if your priority is long-term compounding and valuation efficiency.

  • 5.5% 10Y total return vs BSX's 155.5%
  • PEG 2.01 vs MDT's 36.00
  • 28.2% margin vs NPCE's -31.9%
Best for: long-term compounding and valuation efficiency
MDT
Medtronic plc
The Income Pick

MDT carries the broadest edge in this set and is the clearest fit for income & stability.

  • Dividend streak 36 yrs, beta 0.47, yield 3.6%
  • Lower P/E (14.1x vs 16.7x)
  • 3.6% yield; 36-year raise streak; the other 3 pay no meaningful dividend
  • 175.8% ROA vs NPCE's -29.7%, ROIC 6.0% vs -18.0%
Best for: income & stability
BSX
Boston Scientific Corporation
The Defensive Pick

BSX is the clearest fit if your priority is sleep-well-at-night and defensive.

  • Lower volatility, beta 0.34, Low D/E 50.7%, current ratio 1.62x
  • Beta 0.34, current ratio 1.62x
  • Beta 0.34 vs NPCE's 1.09, lower leverage
Best for: sleep-well-at-night and defensive
See the full category breakdown
CategoryWinnerWhy
GrowthNPCE logoNPCE25.1% revenue growth vs MDT's 3.6%
ValueMDT logoMDTLower P/E (14.1x vs 16.7x)
Quality / MarginsISRG logoISRG28.2% margin vs NPCE's -31.9%
Stability / SafetyBSX logoBSXBeta 0.34 vs NPCE's 1.09, lower leverage
DividendsMDT logoMDT3.6% yield; 36-year raise streak; the other 3 pay no meaningful dividend
Momentum (1Y)NPCE logoNPCE+59.2% vs BSX's -46.0%
Efficiency (ROA)MDT logoMDT175.8% ROA vs NPCE's -29.7%, ROIC 6.0% vs -18.0%

NPCE vs ISRG vs MDT vs BSX — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

NPCENeuroPace, Inc.

Segment breakdown not available.

ISRGIntuitive Surgical, Inc.
FY 2025
Instruments and Accessories
59.8%$6.0B
Systems
24.6%$2.5B
Services
15.6%$1.6B
MDTMedtronic plc
FY 2025
Cardiac and Vascular Group
37.3%$12.5B
Neuroscience Group
29.4%$9.8B
Medical Surgical
25.1%$8.4B
Diabetes Group
8.2%$2.8B
BSXBoston Scientific Corporation
FY 2025
Cardiovascular
66.0%$13.3B
MedSurg
34.0%$6.8B

NPCE vs ISRG vs MDT vs BSX — Financial Metrics

Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLMDTLAGGINGBSX

Income & Cash Flow (Last 12 Months)

Evenly matched — NPCE and ISRG each lead in 3 of 6 comparable metrics.

MDT is the larger business by revenue, generating $35.5B annually — 354.9x NPCE's $100M. ISRG is the more profitable business, keeping 28.2% of every revenue dollar as net income compared to NPCE's -31.9%. On growth, NPCE holds the edge at +23.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricNPCE logoNPCENeuroPace, Inc.ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plcBSX logoBSXBoston Scientific…
RevenueTrailing 12 months$100M$10.6B$35.5B$20.1B
EBITDAEarnings before interest/tax-$14M$3.8B$9.4B$4.7B
Net IncomeAfter-tax profit-$32M$3.0B$4.6B$2.9B
Free Cash FlowCash after capex-$11M$2.8B$5.4B$3.6B
Gross MarginGross profit ÷ Revenue+77.2%+66.3%+61.9%+69.0%
Operating MarginEBIT ÷ Revenue-16.3%+30.5%+17.9%+19.8%
Net MarginNet income ÷ Revenue-31.9%+28.2%+13.0%+14.4%
FCF MarginFCF ÷ Revenue-11.2%+26.8%+15.2%+18.1%
Rev. Growth (YoY)Latest quarter vs prior year+23.9%+23.0%+8.8%+15.9%
EPS Growth (YoY)Latest quarter vs prior year+55.6%+18.8%-11.9%+18.5%
Evenly matched — NPCE and ISRG each lead in 3 of 6 comparable metrics.

Valuation Metrics

MDT leads this category, winning 5 of 7 comparable metrics.

At 21.6x trailing earnings, MDT trades at a 63% valuation discount to ISRG's 57.6x P/E. Adjusting for growth (PEG ratio), ISRG offers better value at 2.65x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.

MetricNPCE logoNPCENeuroPace, Inc.ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plcBSX logoBSXBoston Scientific…
Market CapShares × price$648M$161.1B$99.9B$84.1B
Enterprise ValueMkt cap + debt − cash$697M$158.0B$126.2B$94.5B
Trailing P/EPrice ÷ TTM EPS-29.23x57.62x21.60x29.16x
Forward P/EPrice ÷ next-FY EPS est.43.84x14.13x16.75x
PEG RatioP/E ÷ EPS growth rate2.65x36.00x
EV / EBITDAEnterprise value multiple43.62x14.32x25.30x
Price / SalesMarket cap ÷ Revenue6.48x16.00x2.98x4.19x
Price / BookPrice ÷ Book value/share33.17x9.17x2.08x3.46x
Price / FCFMarket cap ÷ FCF64.67x19.28x22.99x
MDT leads this category, winning 5 of 7 comparable metrics.

Profitability & Efficiency

ISRG leads this category, winning 5 of 9 comparable metrics.

ISRG delivers a 16.9% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-157 for NPCE. ISRG carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NPCE's 3.72x. On the Piotroski fundamental quality scale (0–9), BSX scores 7/9 vs NPCE's 3/9, reflecting strong financial health.

MetricNPCE logoNPCENeuroPace, Inc.ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plcBSX logoBSXBoston Scientific…
ROE (TTM)Return on equity-157.1%+16.9%+9.4%+12.4%
ROA (TTM)Return on assets-29.7%+14.8%+175.8%+6.9%
ROICReturn on invested capital-18.0%+15.0%+6.0%+8.8%
ROCEReturn on capital employed-19.5%+16.5%+7.5%+11.1%
Piotroski ScoreFundamental quality 0–93667
Debt / EquityFinancial leverage3.72x0.02x0.59x0.51x
Net DebtTotal debt minus cash$49M-$3.1B$26.3B$10.4B
Cash & Equiv.Liquid assets$22M$3.4B$2.2B$2.0B
Total DebtShort + long-term debt$71M$303M$28.5B$12.4B
Interest CoverageEBIT ÷ Interest expense-0.83x9.08x11.03x
ISRG leads this category, winning 5 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

NPCE leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in ISRG five years ago would be worth $15,873 today (with dividends reinvested), compared to $7,230 for MDT. Over the past 12 months, NPCE leads with a +59.2% total return vs BSX's -46.0%. The 3-year compound annual growth rate (CAGR) favors NPCE at 55.6% vs MDT's -1.4% — a key indicator of consistent wealth creation.

MetricNPCE logoNPCENeuroPace, Inc.ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plcBSX logoBSXBoston Scientific…
YTD ReturnYear-to-date+27.2%-19.3%-18.1%-40.3%
1-Year ReturnPast 12 months+59.2%-15.4%-2.8%-46.0%
3-Year ReturnCumulative with dividends+276.4%+49.6%-4.2%+6.5%
5-Year ReturnCumulative with dividends-8.8%+58.7%-27.7%+31.2%
10-Year ReturnCumulative with dividends-22.7%+554.2%+26.5%+155.5%
CAGR (3Y)Annualised 3-year return+55.6%+14.4%-1.4%+2.1%
NPCE leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

Evenly matched — NPCE and BSX each lead in 1 of 2 comparable metrics.

BSX is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than NPCE's 1.09 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NPCE currently trades 99.2% from its 52-week high vs BSX's 51.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricNPCE logoNPCENeuroPace, Inc.ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plcBSX logoBSXBoston Scientific…
Beta (5Y)Sensitivity to S&P 5001.09x1.02x0.47x0.34x
52-Week HighHighest price in past year$19.44$603.88$106.33$109.50
52-Week LowLowest price in past year$7.56$427.84$77.16$54.98
% of 52W HighCurrent price vs 52-week peak+99.2%+75.1%+73.3%+51.7%
RSI (14)Momentum oscillator 0–10072.242.427.333.2
Avg Volume (50D)Average daily shares traded202K1.8M7.8M15.5M
Evenly matched — NPCE and BSX each lead in 1 of 2 comparable metrics.

Analyst Outlook

MDT leads this category, winning 1 of 1 comparable metric.

Analyst consensus: NPCE as "Buy", ISRG as "Buy", MDT as "Buy", BSX as "Buy". Consensus price targets imply 61.4% upside for BSX (target: $91) vs -1.5% for NPCE (target: $19). MDT is the only dividend payer here at 3.57% yield — a key consideration for income-focused portfolios.

MetricNPCE logoNPCENeuroPace, Inc.ISRG logoISRGIntuitive Surgica…MDT logoMDTMedtronic plcBSX logoBSXBoston Scientific…
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuy
Price TargetConsensus 12-month target$19.00$622.60$109.50$91.33
# AnalystsCovering analysts10554943
Dividend YieldAnnual dividend ÷ price+3.6%
Dividend StreakConsecutive years of raises360
Dividend / ShareAnnual DPS$2.78
Buyback YieldShare repurchases ÷ mkt cap+7.6%+1.4%+3.2%0.0%
MDT leads this category, winning 1 of 1 comparable metric.
Key Takeaway

MDT leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). ISRG leads in 1 (Profitability & Efficiency). 2 tied.

Best OverallMedtronic plc (MDT)Leads 2 of 6 categories
Loading custom metrics...

NPCE vs ISRG vs MDT vs BSX: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is NPCE or ISRG or MDT or BSX a better buy right now?

For growth investors, NeuroPace, Inc.

(NPCE) is the stronger pick with 25. 1% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate NeuroPace, Inc. (NPCE) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — NPCE or ISRG or MDT or BSX?

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

6x versus Intuitive Surgical, Inc. at 57. 6x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Intuitive Surgical, Inc. wins at 2. 01x versus Medtronic plc's 36. 00x.

03

Which is the better long-term investment — NPCE or ISRG or MDT or BSX?

Over the past 5 years, Intuitive Surgical, Inc.

(ISRG) delivered a total return of +58. 7%, compared to -27. 7% for Medtronic plc (MDT). Over 10 years, the gap is even starker: ISRG returned +554. 2% versus NPCE's -22. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — NPCE or ISRG or MDT or BSX?

By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.

34β versus NeuroPace, Inc. 's 1. 09β — meaning NPCE is approximately 218% more volatile than BSX relative to the S&P 500. On balance sheet safety, Intuitive Surgical, Inc. (ISRG) carries a lower debt/equity ratio of 2% versus 4% for NeuroPace, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — NPCE or ISRG or MDT or BSX?

By revenue growth (latest reported year), NeuroPace, Inc.

(NPCE) is pulling ahead at 25. 1% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to 22. 6% for Intuitive Surgical, Inc.. Over a 3-year CAGR, NPCE leads at 30. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — NPCE or ISRG or MDT or BSX?

Intuitive Surgical, Inc.

(ISRG) is the more profitable company, earning 28. 4% net margin versus -31. 9% for NeuroPace, Inc. — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ISRG leads at 29. 3% versus -16. 3% for NPCE. At the gross margin level — before operating expenses — NPCE leads at 77. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is NPCE or ISRG or MDT or BSX more undervalued right now?

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Intuitive Surgical, Inc. (ISRG) is the more undervalued stock at a PEG of 2. 01x versus Medtronic plc's 36. 00x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 43. 8x for Intuitive Surgical, Inc. — 29. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.

08

Which pays a better dividend — NPCE or ISRG or MDT or BSX?

In this comparison, MDT (3.

6% yield) pays a dividend. NPCE, ISRG, BSX do not pay a meaningful dividend and should not be held primarily for income.

09

Is NPCE or ISRG or MDT or BSX better for a retirement portfolio?

For long-horizon retirement investors, Medtronic plc (MDT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

47), 3. 6% yield). Both have compounded well over 10 years (MDT: +26. 5%, NPCE: -22. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between NPCE and ISRG and MDT and BSX?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NPCE is a small-cap high-growth stock; ISRG is a mid-cap high-growth stock; MDT is a mid-cap income-oriented stock; BSX is a mid-cap high-growth stock. MDT pays a dividend while NPCE, ISRG, BSX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

NPCE

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Gross Margin > 46%
Run This Screen
Stocks Like

ISRG

High-Growth Quality Leader

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 11%
  • Net Margin > 16%
Run This Screen
Stocks Like

MDT

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 7%
Run This Screen
Stocks Like

BSX

High-Growth Compounder

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 7%
  • Net Margin > 8%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform NPCE and ISRG and MDT and BSX on the metrics below

Revenue Growth>
%
(NPCE: 23.9% · ISRG: 23.0%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.